|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F-24, Cleveland, OH 44195
(Email: murthys1@ccf.org).
| The first 20% of the full text of this article appears below. |
Obstructing tracheobronchial disease, particularly when resection and reconstruction is not an option, poses significant management difficulty. The cause is largely malignant or a sequela of cancer treatment (eg, radiation induced), although systemic inflammatory disease is occasionally implicated. Length of involved airway, patient fitness, disseminated malignancy or prior therapy, or a combination of these can affect treatment options, which are generally palliative and primarily center on restoration of airway patency through endobronchial stenting.
Stents are broadly divided into silicon-expanding and self-expanding metallic types
Related Article
Ann. Thorac. Surg. 2008 85: 2100-2103.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |